These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 38518602

  • 1. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
    Jiang P, Zeng Y, Yang W, Li L, Zhou L, Xiao L, Li Y, Gu B, Li X, Li J, Li W, Guo L.
    Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
    [Abstract] [Full Text] [Related]

  • 2. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C, Sun Y, Yang Q, Zhou F, Chen X, Wu L, Sun L, Han J.
    Mol Pharm; 2021 Aug 02; 18(8):2906-2923. PubMed ID: 34240881
    [Abstract] [Full Text] [Related]

  • 3. Development of a novel Fc fusion protein dual glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists.
    Jiang P, Sun N, Yang W, Xiao L, Zhou L, Gu B, Li Y, Li L, Li J, Li X, Li W, Guo L.
    Diabetes Obes Metab; 2023 Nov 02; 25(11):3356-3365. PubMed ID: 37580307
    [Abstract] [Full Text] [Related]

  • 4. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.
    McGlone ER, Hope DCD, Davies I, Dore M, Goldin R, Jones B, Liu Z, Li JV, Vorkas PA, Khoo B, Carling D, Minnion J, Bloom SR, Tan TM.
    Biomed Pharmacother; 2024 Jul 02; 176():116888. PubMed ID: 38861859
    [Abstract] [Full Text] [Related]

  • 5. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R, Herling AW, Bossart M, Weiss T, Zhang B, Wenski P, Wandschneider J, Kleutsch S, Butty U, Kannt A, Wagner M, Haack T, Evers A, Dudda A, Lorenz M, Keil S, Larsen PJ.
    Diabetes Obes Metab; 2018 Aug 02; 20(8):1836-1851. PubMed ID: 29938884
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity.
    Li Q, Yang Q, Han J, Liu X, Fu J, Yin J.
    Chin J Nat Med; 2022 Nov 02; 20(11):863-872. PubMed ID: 36427920
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
    Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, Jansson-Löfmark R, Naylor J, Rossi A, Bednarek MA, Bhagroo N, Salari H, Will S, Oldham S, Hansen G, Feigh M, Klein T, Grimsby J, Maguire S, Jermutus L, Rondinone CM, Coghlan MP.
    Diabetes Obes Metab; 2016 Dec 02; 18(12):1176-1190. PubMed ID: 27377054
    [Abstract] [Full Text] [Related]

  • 16. Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist.
    Yuan Y, Yan Z, Lao Q, Jiang N, Wu S, Lu Q, Han J, Zhao S.
    Eur J Med Chem; 2023 Feb 05; 247():115036. PubMed ID: 36571995
    [Abstract] [Full Text] [Related]

  • 17. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
    Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, Bajrami B, Rist W, Uphues I, Drucker DJ, Klein H, Santhanam R, Hamprecht D, Neubauer H, Augustin R.
    Mol Metab; 2022 Dec 05; 66():101633. PubMed ID: 36356832
    [Abstract] [Full Text] [Related]

  • 18. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
    Pei Z, Zhou D, Yan J, Wang S, Yang X, Pei Z.
    Life Sci; 2020 Jul 15; 253():117651. PubMed ID: 32304764
    [Abstract] [Full Text] [Related]

  • 19. Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists.
    Jiang N, Jing L, Li Q, Su S, Yang Q, Zhou F, Chen X, Han J, Tang C, Tang W.
    Eur J Med Chem; 2021 Feb 15; 212():113118. PubMed ID: 33422984
    [Abstract] [Full Text] [Related]

  • 20. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
    Killion EA, Wang J, Yie J, Shi SD, Bates D, Min X, Komorowski R, Hager T, Deng L, Atangan L, Lu SC, Kurzeja RJM, Sivits G, Lin J, Chen Q, Wang Z, Thibault SA, Abbott CM, Meng T, Clavette B, Murawsky CM, Foltz IN, Rottman JB, Hale C, Véniant MM, Lloyd DJ.
    Sci Transl Med; 2018 Dec 19; 10(472):. PubMed ID: 30567927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.